United States. Securities and Exchange Commission
Coherus BioSciences, Inc. has filed a Current Report with the U.S. Securities and Exchange Commission announcing the appointment of Michael Ryan, Pharm.D., to its Board of Directors. Dr. Ryan brings over four decades of experience in academia and the biopharmaceutical industry, having served in various leadership roles, including
United States. Securities and Exchange Commission
Pieris Pharmaceuticals, Inc. has filed a Current Report with the U.S. Securities and Exchange Commission, announcing the termination of its License and Collaboration Agreement with AstraZeneca AB, effective October 15, 2023. This development comes after AstraZeneca provided a written notice of termination on July 17, 2023, citing non-clinical safety
United States. Securities and Exchange Commission
Caribou Biosciences, Inc., a biotechnology company developing novel cell therapies, has secured $25 million in financing from Pfizer Inc. through a private placement transaction. The deal represents a significant milestone for Caribou Biosciences, allowing the company to further develop its allogeneic anti-BCMA CAR-T cell therapy, CB-011. The private placement agreement
United States. Securities and Exchange Commission
Mallinckrodt plc, a global biopharmaceutical company, has engaged in discussions with stakeholders, including parties holding substantial positions across its capital structure and representatives of the Opioid Master Disbursement Trust II. The company is actively evaluating its capital needs in light of its obligations under its opioid settlement and long-term debt,
United States. Securities and Exchange Commission
Bed Bath & Beyond, a leading American domestic merchandise closeout store, has filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) on June 22, 2023, following its filing for Chapter 11 bankruptcy protection on April 23, 2023. The company has entered into an Asset Purchase Agreement
United States. Securities and Exchange Commission
Amedisys Inc., a healthcare company, has filed a Form 8-K report with the U.S. Securities and Exchange Commission on June 21, 2023, disclosing the expiration of the Hart-Scott-Rodino Antitrust Act waiting period for its proposed merger with Option Care Health, Inc. The merger remains subject to customary closing conditions
United States. Securities and Exchange Commission
Seagen Inc. has announced that it has entered into an Agreement and Plan of Merger with Pfizer Inc. and Aris Merger Sub, Inc., with the Company set to be acquired by Pfizer in a deal that remains subject to regulatory approvals and other closing conditions. The merger agreement was first
United States. Securities and Exchange Commission
On June 12, 2023, Credit Suisse High Yield Bond Fund filed a Form 8-K with the U.S. Securities and Exchange Commission, detailing the impact of the merger between Credit Suisse Group AG and UBS Group AG. As a result of the merger, Credit Suisse High Yield Bond Fund'
United States. Securities and Exchange Commission
Amgen Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission, announcing updates on the acquisition of Horizon Therapeutics. According to the report, the U.S. Federal Trade Commission (FTC) filed a complaint seeking a temporary restraining order and preliminary injunction enjoining the acquisition. The court
United States. Securities and Exchange Commission
Mallinckrodt plc, a pharmaceutical company based in Ireland, has been facing significant financial pressure as it navigates its obligations under the opioid settlement. The company, which has been struggling with financial issues, has received unsolicited letters from investors holding substantial positions in the company's capital structure. These investors,
United States. Securities and Exchange Commission
Enstar Group Limited has entered into a $800 million amended and restated revolving credit agreement with lenders, replacing its existing revolving credit facility. The five-year agreement, set to expire on May 30, 2028, provides a revolving commitment of $800 million and allows for additional commitments of up to $200 million.
United States. Securities and Exchange Commission
At its 2023 Annual Meeting of Stockholders, BioMarin Pharmaceutical Inc. received shareholder approval for an amendment to the company's 2017 Equity Incentive Plan, increasing the number of shares reserved for issuance by 14 million. The company's shareholders also elected 11 directors to serve on the board,
